Translational Research in Cancer Genomic Medicine

癌症基因组医学转化研究

• 批准号: 7168666
• 负责人: Wen-Hwa Lee
• 金额: $ 22.33万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-24 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7168666
• 关键词: Medicine; Translational Research; cancer genomics

DESCRIPTION (provided by applicant): Support is requested to initiate a comprehensive training program in Translational Research in Cancer Genomic Medicine (TRCGM) at the University of California, Irvine. Intensive biomedical research efforts have yielded significant advances in clinical outcomes for a subset of cancers. However, developing useful and effective drugs for treating cancer remains a great challenge. Over the last several years, because of the completion of the human genome, the improved understanding of network connections in cellular regulatory pathways and advance in chemical biology, a plethora of new potential drug targets has been identified through the persistent work in many academic research institutions. These drug targets hold the promise of eventually resulting in the next generation of anti-cancer drugs. UCI has strong programs in basic and clinical cancer research, chemical biology, the development and use of animal models for cancer research. However, until now, no strategy has combined and leveraged these strengths of academic centers in order to train researchers who will be able to integrate basic science with all the aspects of drug development. The 18 proposed faculty were selected as the program faculty for the TRCGM because their research has an important translational component and all are interested in training future translational fellows. The program will focus on training graduate students and postdoctoral and medical fellows in cancer research areas that are highly related to translational research including target identification, chemical biology, preclinical animal models, and clinical trials. Trainees in this program will develop a thorough understanding of the steps required to translate laboratory findings into drugs that may significantly benefit patients in a clinical setting. The NIH has recognized the need for such training in its Roadmap Initiatives. The TRCGM will meet these needs and will train a new cadre of cancer researchers who are able to rapidly and effectively translate laboratory research into medicine, which will improve clinical outcomes by reducing cancer morbidity and mortality.

描述（由申请人提供）：请求支持在加州大学欧文分校启动癌症基因组医学转化研究（TRCGM）的综合培训计划。密集的生物医学研究工作在一部分癌症的临床结果方面取得了重大进展。然而，开发用于治疗癌症的有用和有效的药物仍然是一个巨大的挑战。在过去的几年里，由于人类基因组的完成，对细胞调控通路网络连接的理解的提高以及化学生物学的进步，通过许多学术研究机构的持续工作，已经确定了大量新的潜在药物靶点。这些药物靶点有望最终产生下一代抗癌药物。 UCI在基础和临床癌症研究，化学生物学，癌症研究动物模型的开发和使用方面拥有强大的计划。然而，到目前为止，还没有一种战略能够结合和利用学术中心的这些优势，以培养能够将基础科学与药物开发的各个方面相结合的研究人员。18所拟议的教师被选为TRCGM的项目教师，因为他们的研究具有重要的翻译组成部分，并且都对培训未来的翻译研究员感兴趣。该计划将侧重于培养研究生和博士后以及与转化研究高度相关的癌症研究领域的医学研究员，包括靶标识别，化学生物学，临床前动物模型和临床试验。该计划的学员将全面了解将实验室发现转化为药物所需的步骤，这些药物可能会使临床环境中的患者显着受益。国家卫生研究院在其路线图倡议中认识到了这种培训的必要性。TRCGM将满足这些需求，并将培养一批新的癌症研究人员，他们能够迅速有效地将实验室研究转化为医学，这将通过降低癌症发病率和死亡率来改善临床结果。